BioNTech's Breast Cancer Candidate Clears Its Bar, but the Payoff Looks Thin
Published on 11/04/2026 at 15:51 | Editorial boerse-global.de
BioNTech and DualityBio have a statistical win on their hands — and a commercial question mark to go with it. The partners disclosed on 26 October that the Phase 3 DYNASTY-Breast02 trial of their breast cancer drug trastuzumab pamirtecan met its primary endpoint, yet both companies were quick to temper expectations about what that result is actually worth in today's treatment landscape.
The endpoint in question was progression-free survival, the stretch of time a patient lives without the disease worsening. Trastuzumab pamirtecan beat chemotherapy by a margin that was statistically significant but, by the companies' own account, only moderate. Overall survival data had not yet matured. Formal success and therapeutic value, in other words, are two different things — and BioNTech and DualityBio framed the potential benefit as limited once efficacy and safety are weighed side by side.
Safety is a big part of that calculus. Reuters reported a higher incidence of interstitial lung disease among treated patients, including severe and fatal cases. Those findings sit alongside the modest efficacy advantage as the partners weigh next steps, which they said would be discussed in light of the available efficacy and safety data.
Roche Takes the Reins on a Shared Program
Pipeline news elsewhere came with a clearer financial shape. BioNTech said it had exercised an option in its alliance with Roche and Genentech under which the two partners will, from 1 January 2027, generally carry the future research and development costs of the shared program. BioNTech stands to collect royalties if development and commercialization go well — a payout tied entirely to the program's success. Guidance for its own adjusted R&D spend and adjusted sales and administrative costs was left untouched.
Should investors sell immediately? Or is it worth buying BioNTech?
A second collaboration, announced with Gilead Sciences on 22 October, will see study drugs supplied for a combination of pumitamig with Gilead's sacituzumab govitecan. The vehicle is the global Phase 3 ROSETTA Breast-01 trial, subject to regulatory clearance, in patients with previously untreated, locally advanced or metastatic triple-negative breast cancer whose tumors show low or no PD-L1 expression.
A Thinner Top Line, a Wider Loss
The quarterly figures provide the backdrop. Revenue for the third quarter of 2026 came in at EUR 1,289.2 million, down from EUR 1,518.9 million a year earlier, a decline BioNTech attributed chiefly to weaker demand for COVID-19 vaccines. IFRS net profit for the quarter reached EUR 184.5 million.
The nine-month picture is less forgiving: a net loss of EUR 1,168.2 million on revenue of EUR 1,512.9 million. Even so, BioNTech nudged up the midpoint of its 2026 revenue guidance, now set at EUR 1.7 billion to EUR 1.9 billion.
BioNTech at a turning point? This analysis reveals what investors need to know now.
Not everything ran smoothly on the home front. According to a dpa-AFX report published yesterday, the company's works council has criticized management's handling of employees in a letter to the executive board — friction running in parallel with the broader transformation under way at the company.
Ad
BioNTech Stock: New Analysis - 4 November
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
